Sept 8 (Reuters) - GlaxoSmithKline Plc andits partner Theravance Inc on Tuesday said theirinhaled medicine Breo failed in a huge, high-stakes clinicaltrial to prolong life of patients with chronic pulmonaryrespiratory disease.
Investors had hoped the 16,500-patient study, called SUMMIT,would increase demand for the medicine, which was approved in2013 for COPD, and boost its annual sales by billions ofdollars.
(Reporting by Ransdell Pierson; Editing by Chris Reese)